The Valley Desk

LetterClinicoEconomics and outcomes research : CEORPublished

Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma [Letter]

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Letter
Venue
ClinicoEconomics and outcomes research : CEOR
Published
PubMed ID
40756255
PubMed Central ID
PMC12318513
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal